RxDoctor Payments Data

Sanjeev Sharma, MD

Family Medicine · Omaha, NENPI 1366556839

Payments from drug & device makers

$220in general payments, 2019–2025

Across 15 payments — averaging $14.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$46
  • AstraZeneca$44
  • Amgen$27
  • GSK$24
  • Amarin Pharma, Inc.$19
  • Pfizer$18
  • plus $44 from 3 others

What the payments were for

  • Food & beverage$220100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk3$46
AstraZeneca3$44
Amgen2$27
GSK2$24
Amarin Pharma, Inc.1$19
Pfizer1$18
AbbVie1$15
Merck1$15
Exact Sciences1$14

How this compares

$220 in reported general payments places this provider in the 35th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$59,051
Medicare patients
201
Services billed
882

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide77$90,086
JardianceEmpagliflozin73$80,311
OzempicSemaglutide56$68,579
EliquisApixaban59$52,317
MounjaroTirzepatide27$44,818
FarxigaDapagliflozin Propanediol26$31,961
JanuviaSitagliptin Phosphate28$26,733
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$22,277
TradjentaLinagliptin27$18,484
SymbicortBudesonide/Formoterol Fumarate34$14,274
LinzessLinaclotide14$10,328
RestasisCyclosporine14$9,332
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$7,925
DuleraMometasone/Formoterol17$5,987
Atorvastatin Calcium662$5,984

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$46$68,57956 claims
PfizerEliquis$18$52,31759 claims
AstraZenecaFarxiga, Symbicort$44$46,23560 claims
MerckJanuvia, Dulera$15$32,72045 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$24$30,52354 claims
AbbVieLinzess, Restasis, Synthroid$15$20,42044 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →